Samer Khaled, MD
Hematology & Oncology · Orlando, FLNPI 1376785006
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AstraZeneca at 42.2% of the total. Reporting peaked in 2019 at $41,471 and has fallen 77.7% since, to $9,250 in 2025.
Across 89 payments — averaging $773.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Daiichi Sankyo Inc.$13K
- Omeros Corporation$11K
- Gilead$9K
- Astellas Pharma US Inc$3K
- Novartis$3K
- plus $779 from 10 others
Across 134 payments — averaging $1119.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$69K
- Daiichi Sankyo Inc.$37K
- Otsuka Pharmaceutical Co., Ltd.$19K
- AstraZeneca$13K
- Janssen Research & Development, LLC$7K
- Omeros Corporation$5K
What the payments were for
- Consulting fees$16,70024%
- Speaking & faculty fees$27,34240%
- Travel & lodging$20,49230%
- Food & beverage$3,2995%
- Education$9691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $29,037 |
| Daiichi Sankyo Inc. | 5 | $12,805 |
| Omeros Corporation | 17 | $11,363 |
| Gilead | 12 | $9,043 |
| Astellas Pharma US Inc | 2 | $3,032 |
| Novartis | 2 | $2,743 |
| Sanofi | 2 | $149 |
| Johnson & Johnson | 1 | $146 |
| Jazz Pharmaceuticals Inc. | 1 | $129 |
| Adaptive Biotechnologies Corporation | 1 | $112 |
| Dexcom, Inc. | 4 | $90 |
| Sobi, Inc | 1 | $64 |
| Legend Biotech USA Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,802 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Daniel LandauOrlando$1.8M
- Shahram MoriOrlando$952K
- Sajeve ThomasOrlando$639K
- Nikita ShahOrlando$470K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.